“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Improves Quality of Life in Psoriasis: Results from a Phase 2 Study”. 2019. SKIN The Journal of Cutaneous Medicine 3 (November): S12. https://doi.org/10.25251/skin.3.supp.12.